MARKET

PTE

PTE

Polarityte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.520
+0.070
+4.83%
Pre Market: 1.520 0 0.00% 08:00 07/05 EDT
OPEN
1.470
PREV CLOSE
1.450
HIGH
1.530
LOW
1.420
VOLUME
26
TURNOVER
--
52 WEEK HIGH
25.50
52 WEEK LOW
1.410
MARKET CAP
6.79M
P/E (TTM)
-0.3017
1D
5D
1M
3M
1Y
5Y
Anebulo, Tenon top healthcare gainers; BioSig, Rigel lead losers' pack
Gainers: Anebulo Pharmaceuticals (ANEB) +32%. Tenon Medical (TNON) +19%. PolarityTE (PTE) +14%. TRACON Pharmaceuticals (TCON) +14%. Bausch Health (BHC) +13%. Losers: BioSig Technologies (BSGM) -26%. Rigel Pharmaceuticals (RIGL) -8%. Valneva (VALN) -8%. Mer...
Seekingalpha · 06/24 14:05
PolarityTE's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PolarityTE's (NASDAQ:PTE) reported sales totaled $741.00 thousand. Despite a 55.99% increase in earnings, the company posted a loss of $3.77 million.
Benzinga · 06/21 13:49
ACADIA Pharmaceuticals, GeoPark, Gran Tierra Energy among premarket losers' pack
Fujian Blue Hat Interactive Entertainment Technology (BHAT) -45%. ACADIA Pharmaceuticals (ACAD) -33% as trading resumes after FDA snub for antipsychotic drug. Addex Therapeutics (ADXN) -11%. Kazia Therapeutics (KZIA) -7%. Gran Tierra Energy
Seekingalpha · 06/21 12:24
PolarityTE files secondary offering for up to 4.75M shares
PolarityTE (NASDAQ:PTE) on Friday filed a preliminary prospectus with the U.S. SEC for the offering and resale of up to 4.75M shares by a selling shareholder. The selling shareholder is
Seekingalpha · 06/17 20:57
BRIEF-Polarityte Inc Files Preliminary Prospectus For 4.8 Million Shares Of Common Stock Offered By The Selling Stockholder - SEC Filing
reuters.com · 06/17 20:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 06/06 12:34
PolarityTE to raise $8M in registered direct and private placement offerings
PolarityTE (NASDAQ:PTE) trades 6.3% down premarket after it entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1.58M shares at a purchase price of $2.525/share
Seekingalpha · 06/06 12:11
PolarityTE Announces $8M Registered Direct And Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single
Benzinga · 06/06 12:04
More
No Data
Learn about the latest financial forecast of PTE. Analyze the recent business situations of Polarityte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PTE stock price target is 23.75 with a high estimate of 28.75 and a low estimate of 18.75.
High28.75
Average23.75
Low18.75
Current 1.535
EPS
Actual
Estimate
-2.34-1.75-1.17-0.58
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 100
Institutional Holdings: 3.40M
% Owned: 84.59%
Shares Outstanding: 4.46M
TypeInstitutionsShares
Increased
10
17.79K
New
9
364.30K
Decreased
7
86.88K
Sold Out
6
36.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.50%
Pharmaceuticals & Medical Research
+0.12%
Key Executives
Non-Executive Chairman/Independent Director
Peter Cohen
President/Chief Executive Officer
Richard Hague
Chief Financial Officer
Jacob Patterson
Executive Vice President/General Counsel/Secretary
Cameron Hoyler
Director
David Seaburg
Independent Director
Willie Bogan
Independent Director
Jeff Dyer
Independent Director
Chris Nolet
No Data
No Data
About PTE
PolarityTE, Inc. is a biotechnology company. The Company is focused on developing regenerative tissue products and biomaterials. It also operates a laboratory testing and clinical research business using equipment, personnel, and facilities it acquired to advance its development of regenerative tissue products. Its first regenerative tissue product is SkinTE, which is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The Company's development projects include SkinTE Cryo, SkinTE point-of-care device, PTE 11000, and others.

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.